Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorInal, Ali
dc.contributor.authorCiltas, Aydin
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorBerk, Veli
dc.contributor.authorKos, F. Tugba
dc.contributor.authorDane, Faysal
dc.contributor.authorUnek, Ilkay Tugba
dc.date.accessioned2024-04-24T17:28:15Z
dc.date.available2024-04-24T17:28:15Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy has limited impact on overall survival (OS) so that eligible patients should be selected carefully. The aim of this study was to analyze prognostic factors for survival in Turkish advanced pancreatic cancer patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and receiving gemcitabine (Gem) alone or gemcitabine plus cisplatin (GemCis). Methods: This retrospective evaluation was performed for patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and who received gemcitabine between December 2005 and August 2011. Twenty-seven potential prognostic variables were chosen for univariate and multivariate analyses to identify prognostic factors associated with survival. Results: Among the 27 variables in univariate analysis, three were identified to have prognostic significance: sex (p = 0.04), peritoneal dissemination (p = 0.02) and serum creatinine level (p = 0.05). Multivariate analysis by Cox proportional hazard model showed only peritoneal dissemination to be an independent prognostic factor for survival. Conclusion: In conclusion, peritoneal metastasis was identified as an important prognostic factor in metastatic pancreatic cancer patients who survived more than one year from the diagnosis of recurrent and/or metastatic disease and receiving Gem or GemCis. The findings should facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.en_US
dc.identifier.doi10.7314/APJCP.2012.13.5.1841
dc.identifier.endpage1844en_US
dc.identifier.issn1513-7368
dc.identifier.issue5en_US
dc.identifier.pmid22901133
dc.identifier.scopus2-s2.0-84869472821
dc.identifier.scopusqualityQ3
dc.identifier.startpage1841en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.5.1841
dc.identifier.urihttps://hdl.handle.net/11468/20380
dc.identifier.volume13en_US
dc.identifier.wosWOS:000309470100025
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPancreasen_US
dc.subjectCanceren_US
dc.subjectGemcitabinen_US
dc.subjectPrognosisen_US
dc.subjectLong Term Survivorsen_US
dc.titleLong Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Studyen_US
dc.titleLong Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu